Differential pharmacological activity of JN403 between α7 and muscle nicotinic acetylcholine receptors

Hugo R. Arias, Maria Jose De Rosa, Ignacio Bergé, Dominik Feuerbach, Cecilia Bouzat

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The differential action of the novel agonist JN403 at neuronal α7 and muscle nicotinic receptors (AChRs) was explored by using a combination of functional and structural approaches. Single-channel recordings reveal that JN403 is a potent agonist of α7 but a very low-efficacy agonist of muscle AChRs. JN403 elicits detectable openings of α7 and muscle AChRs at concentrations ∼1000-fold lower and ∼20-fold higher, respectively, than that for ACh. Single-channel activity elicited by JN403 is very similar to that elicited by ACh in α7 but profoundly different in muscle AChRs, where openings are brief and infrequent and do not appear in clusters at any concentration. JN403 elicits single-channel activity of muscle AChRs lacking the ε subunit, with opening events being more frequent and prolonged than those of wild-type AChRs. This finding is in line with the molecular docking studies predicting that JN403 may form a hydrogen bond required for potent activation at the α-δ but not at the α-ε binding site. JN403 does not elicit detectable Ca2+ influx in muscle AChRs but inhibits (±)-epibatidine-elicited influx mainly by a noncompetitive mechanism. Such inhibition is compatible with single-channel recordings revealing that JN403 produces open-channel blockade and early termination of ACh-elicited clusters, and it is therefore also a potent desensitizing enhancer of muscle AChRs. The latter mechanism is supported by the JN403-induced increase in the level of binding of [3H]cytisine and [3H]TCP to resting AChRs. Elucidation of the differences in activity of JN403 between neuronal α7 and muscle AChRs provides further insights into mechanisms underlying selectivity for α7 AChRs.

Original languageEnglish
Pages (from-to)8480-8488
Number of pages9
JournalBiochemistry
Volume52
Issue number47
DOIs
StatePublished - 26 Nov 2013
Externally publishedYes

Fingerprint

Nicotinic Receptors
Muscle
Pharmacology
Muscles
epibatidine
(S)-(1-azabicyclo(2.2.2)oct-3-yl)carbamic acid (S)-1-(2-fluorophenyl) ethyl ester
Hydrogen
Hydrogen bonds
Chemical activation
Binding Sites

Cite this

Arias, Hugo R. ; De Rosa, Maria Jose ; Bergé, Ignacio ; Feuerbach, Dominik ; Bouzat, Cecilia. / Differential pharmacological activity of JN403 between α7 and muscle nicotinic acetylcholine receptors. In: Biochemistry. 2013 ; Vol. 52, No. 47. pp. 8480-8488.
@article{3bade2a7724f4aabb0687cc6aa0362df,
title = "Differential pharmacological activity of JN403 between α7 and muscle nicotinic acetylcholine receptors",
abstract = "The differential action of the novel agonist JN403 at neuronal α7 and muscle nicotinic receptors (AChRs) was explored by using a combination of functional and structural approaches. Single-channel recordings reveal that JN403 is a potent agonist of α7 but a very low-efficacy agonist of muscle AChRs. JN403 elicits detectable openings of α7 and muscle AChRs at concentrations ∼1000-fold lower and ∼20-fold higher, respectively, than that for ACh. Single-channel activity elicited by JN403 is very similar to that elicited by ACh in α7 but profoundly different in muscle AChRs, where openings are brief and infrequent and do not appear in clusters at any concentration. JN403 elicits single-channel activity of muscle AChRs lacking the ε subunit, with opening events being more frequent and prolonged than those of wild-type AChRs. This finding is in line with the molecular docking studies predicting that JN403 may form a hydrogen bond required for potent activation at the α-δ but not at the α-ε binding site. JN403 does not elicit detectable Ca2+ influx in muscle AChRs but inhibits (±)-epibatidine-elicited influx mainly by a noncompetitive mechanism. Such inhibition is compatible with single-channel recordings revealing that JN403 produces open-channel blockade and early termination of ACh-elicited clusters, and it is therefore also a potent desensitizing enhancer of muscle AChRs. The latter mechanism is supported by the JN403-induced increase in the level of binding of [3H]cytisine and [3H]TCP to resting AChRs. Elucidation of the differences in activity of JN403 between neuronal α7 and muscle AChRs provides further insights into mechanisms underlying selectivity for α7 AChRs.",
author = "Arias, {Hugo R.} and {De Rosa}, {Maria Jose} and Ignacio Berg{\'e} and Dominik Feuerbach and Cecilia Bouzat",
year = "2013",
month = "11",
day = "26",
doi = "10.1021/bi4012572",
language = "English",
volume = "52",
pages = "8480--8488",
journal = "Biochemistry",
issn = "0006-2960",
number = "47",

}

Differential pharmacological activity of JN403 between α7 and muscle nicotinic acetylcholine receptors. / Arias, Hugo R.; De Rosa, Maria Jose; Bergé, Ignacio; Feuerbach, Dominik; Bouzat, Cecilia.

In: Biochemistry, Vol. 52, No. 47, 26.11.2013, p. 8480-8488.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Differential pharmacological activity of JN403 between α7 and muscle nicotinic acetylcholine receptors

AU - Arias, Hugo R.

AU - De Rosa, Maria Jose

AU - Bergé, Ignacio

AU - Feuerbach, Dominik

AU - Bouzat, Cecilia

PY - 2013/11/26

Y1 - 2013/11/26

N2 - The differential action of the novel agonist JN403 at neuronal α7 and muscle nicotinic receptors (AChRs) was explored by using a combination of functional and structural approaches. Single-channel recordings reveal that JN403 is a potent agonist of α7 but a very low-efficacy agonist of muscle AChRs. JN403 elicits detectable openings of α7 and muscle AChRs at concentrations ∼1000-fold lower and ∼20-fold higher, respectively, than that for ACh. Single-channel activity elicited by JN403 is very similar to that elicited by ACh in α7 but profoundly different in muscle AChRs, where openings are brief and infrequent and do not appear in clusters at any concentration. JN403 elicits single-channel activity of muscle AChRs lacking the ε subunit, with opening events being more frequent and prolonged than those of wild-type AChRs. This finding is in line with the molecular docking studies predicting that JN403 may form a hydrogen bond required for potent activation at the α-δ but not at the α-ε binding site. JN403 does not elicit detectable Ca2+ influx in muscle AChRs but inhibits (±)-epibatidine-elicited influx mainly by a noncompetitive mechanism. Such inhibition is compatible with single-channel recordings revealing that JN403 produces open-channel blockade and early termination of ACh-elicited clusters, and it is therefore also a potent desensitizing enhancer of muscle AChRs. The latter mechanism is supported by the JN403-induced increase in the level of binding of [3H]cytisine and [3H]TCP to resting AChRs. Elucidation of the differences in activity of JN403 between neuronal α7 and muscle AChRs provides further insights into mechanisms underlying selectivity for α7 AChRs.

AB - The differential action of the novel agonist JN403 at neuronal α7 and muscle nicotinic receptors (AChRs) was explored by using a combination of functional and structural approaches. Single-channel recordings reveal that JN403 is a potent agonist of α7 but a very low-efficacy agonist of muscle AChRs. JN403 elicits detectable openings of α7 and muscle AChRs at concentrations ∼1000-fold lower and ∼20-fold higher, respectively, than that for ACh. Single-channel activity elicited by JN403 is very similar to that elicited by ACh in α7 but profoundly different in muscle AChRs, where openings are brief and infrequent and do not appear in clusters at any concentration. JN403 elicits single-channel activity of muscle AChRs lacking the ε subunit, with opening events being more frequent and prolonged than those of wild-type AChRs. This finding is in line with the molecular docking studies predicting that JN403 may form a hydrogen bond required for potent activation at the α-δ but not at the α-ε binding site. JN403 does not elicit detectable Ca2+ influx in muscle AChRs but inhibits (±)-epibatidine-elicited influx mainly by a noncompetitive mechanism. Such inhibition is compatible with single-channel recordings revealing that JN403 produces open-channel blockade and early termination of ACh-elicited clusters, and it is therefore also a potent desensitizing enhancer of muscle AChRs. The latter mechanism is supported by the JN403-induced increase in the level of binding of [3H]cytisine and [3H]TCP to resting AChRs. Elucidation of the differences in activity of JN403 between neuronal α7 and muscle AChRs provides further insights into mechanisms underlying selectivity for α7 AChRs.

UR - http://www.scopus.com/inward/record.url?scp=84888601903&partnerID=8YFLogxK

U2 - 10.1021/bi4012572

DO - 10.1021/bi4012572

M3 - Article

C2 - 24164482

AN - SCOPUS:84888601903

VL - 52

SP - 8480

EP - 8488

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 47

ER -